Literature DB >> 29777341

Improvement of neurological and ocular symptoms of Behçet's disease after the introduction of infliximab.

Marko Barešić1, Mirna Reihl2, Mario Habek3, Nenad Vukojević4, Branimir Anić1.   

Abstract

Behçet's disease is a chronic inflammatory condition of unknown origin characterized by multiple organ involvement. The most common symptoms of Behçet's disease are recurrent oral and/or genital ulcerations in combination with symptoms affecting eyes, skin, central and peripheral nervous system, blood vessels and gastrointestinal tract. We present a 43-year-old female patient with the history of recurrent episodes of genital and oral ulcerations, elevated acute phase reactants and skin lesions. The diagnosis of Behçet's disease has been delayed (for more than 10 years) and reached only after she developed neurological and ocular symptoms. Treatment with glucocorticoids and azathioprine was partially successful. High doses of glucocorticoids were needed to control the disease and cyclosporine A was nephrotoxic. Remission was reached after the introduction of infliximab (plus methotrexate) and glucocorticoids were stopped. In the recent years, infliximab has been accepted as a standard therapy for refractory cases of Behçet's disease (neurological, ocular or gastrointestinal). Our patient presented with refractory ocular and neurological symptoms and infliximab was effective for both manifestations. Long-term side-effects of glucocorticoids and other immunosuppressants can be avoided with TNF-α blockade. We emphasize the importance of a timely and accurate diagnosis and significance of excluding more common diseases in a work-up algorithm.

Entities:  

Keywords:  Behçet’s disease; Glucocorticoids; Infliximab; Neurologic and ocular involvement

Mesh:

Substances:

Year:  2018        PMID: 29777341     DOI: 10.1007/s00296-018-4054-9

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  37 in total

1.  Successful use of infliximab in a patient with neuro-Behçet's disease.

Authors:  Gracia Maria Abalos-Medina; Daniel Sánchez-Cano; Gonzalo Ruiz-Villaverde; Ricardo Ruiz-Villaverde; Susana Quirosa Flores; Enrique Raya Alvarez
Journal:  Int J Rheum Dis       Date:  2009-09       Impact factor: 2.454

2.  Prevalence of Adamantiades-Behçet's disease in Germany and the municipality of Berlin: results of a nationwide survey.

Authors:  N G Papoutsis; M B Abdel-Naser; A Altenburg; H Orawa; I Kötter; L Krause; U Pleyer; D Djawari; R Stadler; U Wollina; P K Kohl; H P M Gollnick; W Kirch; F R Ochsendorf; W Keitel; P Martus; C C Zouboulis
Journal:  Clin Exp Rheumatol       Date:  2006 Sep-Oct       Impact factor: 4.473

3.  EULAR recommendations for the management of Behçet disease.

Authors:  G Hatemi; A Silman; D Bang; B Bodaghi; A M Chamberlain; A Gul; M H Houman; I Kötter; I Olivieri; C Salvarani; P P Sfikakis; A Siva; M R Stanford; N Stübiger; S Yurdakul; H Yazici
Journal:  Ann Rheum Dis       Date:  2008-01-31       Impact factor: 19.103

Review 4.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

5.  Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behçet Study Group.

Authors:  G Akman-Demir; P Serdaroglu; B Tasçi
Journal:  Brain       Date:  1999-11       Impact factor: 13.501

6.  Atypical presentation of Behçet's disease with central nervous system involvement successfully treated with infliximab.

Authors:  U Studer; B Ruehe; G Waldegg; I Vajtai; R Escher; D Aeberli
Journal:  Rheumatol Int       Date:  2011-03-29       Impact factor: 2.631

Review 7.  Drug-induced lupus due to anti-tumor necrosis factor alpha agents.

Authors:  Michelle F Costa; Nuha R Said; Bernard Zimmermann
Journal:  Semin Arthritis Rheum       Date:  2007-10-30       Impact factor: 5.532

8.  Diagnosis/Classification Criteria for Behcet's Disease.

Authors:  Fereydoun Davatchi
Journal:  Patholog Res Int       Date:  2011-09-27

9.  Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients.

Authors:  Fabrizio Cantini; Laura Niccoli; Carlotta Nannini; Olga Kaloudi; Emanuele Cassarà; Massimo Susini; Ivo Lenzetti
Journal:  Biologics       Date:  2011-12-29

10.  Anti-TNF therapy in the management of ocular attacks in an elderly patient with long-standing Behçet's disease.

Authors:  Hisako Karube; Koju Kamoi; Kyoko Ohno-Matsui
Journal:  Int Med Case Rep J       Date:  2016-09-27
View more
  3 in total

1.  [Progress in interferon: A treatment of Behcet syndrome].

Authors:  D Yan; W J Zheng
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-12-18

Review 2.  Treating the Different Phenotypes of Behçet's Syndrome.

Authors:  Alessandra Bettiol; Gulen Hatemi; Lorenzo Vannozzi; Alessandro Barilaro; Domenico Prisco; Giacomo Emmi
Journal:  Front Immunol       Date:  2019-12-06       Impact factor: 7.561

3.  Trisomy 8-positive Polycythemia Vera Complicated with Intestinal Behçet's-like Disease: A New Perspective for a Clinical Approach.

Authors:  Yuki Mori; Fumihiko Iwamoto; Toru Kuno; Shoji Kobayashi; Takashi Yoshida; Tatsuya Yamaguchi; Shinichi Takano; Tetsuo Kondo; Keita Kirito; Nobuyuki Enomoto
Journal:  Intern Med       Date:  2021-11-06       Impact factor: 1.282

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.